• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Adding sargramostim to ipilimumab may improve survival in advanced melanoma

byJeffrey CohenandPriyanka Vedak
November 5, 2014
in Chronic Disease, Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adding sargramostim to ipilimumab for advanced melanoma resulted in improvement in overall survival and fewer adverse events when compared to ipilimumab alone.

2. Adding sargramostim to ipilimumab for advanced melanoma demonstrated no improvement in progression free survival.

Evidence Rating Level: 2 (Good)       

Study Rundown: Melanoma is a leading cause of cancer incidence and mortality in the United States. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and sargramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF) have both been used to treat metastatic melanoma. This phase II randomized trial examined the effect of adding sargramostim to ipilimumab on overall and progression free survival in individuals with advanced melanoma, defined as unresectable stage III or IV disease. While the addition of sargramostim to ipilimumab resulted in an increase in overall survival and fewer adverse events, it did not improve progression free survival.

Strengths of this study include its randomized design and careful use of inclusion and exclusion criteria. However, results may have been influenced by bias due to the lack of investigator blinding and are limited by the short follow-up period. Nevertheless, this study ultimately demonstrated the potential benefits of combined ipilimumab/sargramostim therapy for the treatment of advanced melanoma and emphasizes the need for a larger randomized controlled trial to more fully understand the benefits of this treatment regimen.

Click to read the study, published today in JAMA

Relevant Reading: Improved survival with ipilimumab in patients with metastatic melanoma.

RELATED REPORTS

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

In-Depth [randomized controlled trial]: This study randomized 425 individuals with advanced melanoma (i.e., unresectable stage III or IV disease) to receive ipilimumab and sargramostim or ipilimumab alone to determine if adding sargramostim to ipilimumab improves overall or progression free survival. The participants were predominantly male and Caucasian and the ages of participants ranged from 21-89 years. The median follow-up time was 13.3 months (range 0.03-19.9 months). The addition of sargramostim to ipilimumab resulted in an overall survival benefit (log-rank p=0.01), but not a progression free survival benefit (log-rank p=0.37). The addition of sargramostim to ipilimumab also demonstrated fewer adverse effects than ipilimumab alone, notably with regards to colonic perforation.

More from this author: Ambulances equipped for thrombolysis allow for more rapid stroke treatment, Stem cell transplant may be effective in sickle cell disease, Vitamin D supplementation in the ICU does not improve outcomes [VITdAL-ICU trial], Antibiotic use prevalent among hospitalized patients in the US, Frozen fecal transplant effective for Clostridium difficile infection

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: ipilimumabmelanomasargramostim
Previous Post

Non-obstructive coronary artery disease linked with increased heart attacks, death

Next Post

Modified embryonic stem cells may prolong survival of surgical grafts

RelatedReports

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue
StudyGraphics

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

April 28, 2022
#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent
StudyGraphics

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

April 14, 2022
#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers
StudyGraphics

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

April 12, 2022
#VisualAbstract: Melanoma may be considerably over-diagnosed in white patients in the US
StudyGraphics

#VisualAbstract: Melanoma may be considerably over-diagnosed in white patients in the US

March 24, 2022
Next Post
Modified embryonic stem cells may prolong survival of surgical grafts

Modified embryonic stem cells may prolong survival of surgical grafts

PD/Army

Cost-effectiveness of lung cancer screening with CT estimated

Double-opposing Z-plasty may improve cleft palate outcomes

Double-opposing Z-plasty may improve cleft palate outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe
  • 2 Minute Medicine Rewind July 4, 2022
  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.